Value proposition

Implantable micro-scale device enabling in-vivo electrophysiology and localized drug delivery for Parkinson's Disease

The main goal of the STARDUST project is to realize a novel wireless implantable and independent micro-scale device (200x200x200 μm3) enabling in-vivo electrophysiology, optogenetics and ultra-localized drug delivery in freely moving animals. The device will be used to target specific neural circuits of the brain and test a new therapeutic approach for Parkinson’s Disease.
The methods used in this project are based on cutting-edge miniaturized technology combining integrated chips, microelectromechanical systems (MEMS), local drug delivery, integrated electrodes and micro-scale light emitting diodes (μLEDs), enabling an implantable ultrasonically-powered miniaturized device for in-vivo optogenetics, local drug delivery and electrophysiological monitoring – all in one single device.

The main novelty of the STARDUST project is the convergence of multiple, interdisciplinary fields including optogenetics, triggered drug-delivery, miniaturized ultrasonic energy harvesting, material science and nanoelectronics.

The main ambition of the project is to develop a new technology platform to be used for future implantable in-vivo optogenetic devices for monitoring and treating diseases, with an optional local drug delivery add-on beyond 2025. Establishing proof of concept of the STARDUST platform will be the foundation for other applications within photodynamic therapy such as cancer treatment and other neurological and non-neurological disorders.

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 767092

Parkinson's Disease, Optogenetics, μLEDs, Electrophysiology, Pharmacology, Local drug delivery, and Implantable devices